Now Enrolling Learn More Latest News Jan 21, 2020 Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa View Press Release Jan 15, 2020 Abeona Therapeutics Announces Issuance of U.S. Patent for AIM™ Capsids View Press Release Jan 13, 2020 Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa View Press Release View All Our inspiration Learn More Pipeline Our clinical-stage therapies are designed to deliver functional copies of affected genes to cells using gene transfer technologies. Explore R&D EB-101 In Phase 3 development. Autologous gene-corrected cell therapy for patients with RDEB. Learn More ABO-102 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA). Learn More ABO-101 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type B (MPS IIIB). Learn More Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More
